Prostate Cancer Hormone Therapy Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2032
Description
Persistence Market Research has recently released a comprehensive report on the global Prostate Cancer Hormone Therapy Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the evolving treatment landscape and competitive environment, enabling stakeholders to make informed strategic decisions.
Key Insights:
The prostate cancer hormone therapy market focuses on therapeutic approaches designed to reduce or block the production and action of male hormones (androgens) that stimulate prostate cancer growth. Hormone therapy plays a vital role in treating advanced and metastatic prostate cancer and is often used in combination with other treatment approaches such as radiation therapy or chemotherapy. Continuous advancements in targeted therapies, improved diagnostic methods, and the development of next-generation androgen receptor inhibitors have significantly improved treatment outcomes. Growing awareness about early diagnosis and personalized treatment strategies is further strengthening market growth. Additionally, increasing investments in oncology research and the introduction of innovative drug formulations are expected to expand treatment options and improve patient care over the forecast period.
Market Growth Drivers:
The global prostate cancer hormone therapy market is witnessing strong growth due to the rising prevalence of prostate cancer and increasing awareness regarding early detection and treatment. Advances in targeted therapies and the development of novel androgen receptor inhibitors have significantly improved the effectiveness of hormone therapy treatments. Increasing investments in oncology research, expanding clinical trials, and regulatory approvals for innovative drugs are further supporting market expansion. Additionally, the growing aging male population worldwide, which is more susceptible to prostate cancer, is driving demand for effective hormone therapy options. Improved healthcare infrastructure and expanding access to advanced cancer treatments are also contributing to sustained market growth.
Market Restraints:
Despite the strong growth outlook, the prostate cancer hormone therapy market faces several challenges. High treatment costs associated with advanced hormone therapy drugs may limit accessibility in developing regions and cost-sensitive healthcare systems. Hormone therapies can also cause side effects such as fatigue, bone density loss, metabolic changes, and cardiovascular risks, which may affect patient compliance and long-term treatment outcomes. Additionally, the development of resistance to hormone therapies in certain advanced stages of prostate cancer may reduce treatment effectiveness over time. Regulatory hurdles and lengthy drug approval processes may also delay the introduction of innovative therapies to the market.
Market Opportunities:
The prostate cancer hormone therapy market presents significant growth opportunities driven by continuous innovation in oncology therapeutics. Advances in precision medicine and biomarker-based treatment strategies are creating opportunities for more personalized and effective hormone therapy regimens. Increasing investments in research and development by pharmaceutical companies are expected to lead to the discovery of next-generation androgen receptor inhibitors and combination therapies. Emerging markets in Asia Pacific and Latin America offer substantial growth potential due to improving healthcare infrastructure and increasing awareness about cancer treatment options. Additionally, expanding telemedicine services and online pharmacy distribution channels are expected to enhance patient access to hormone therapy medications.
Key Questions Answered in the Report:
Leading companies in the global prostate cancer hormone therapy market are focusing on research and development, strategic collaborations, and the introduction of innovative drug formulations to strengthen their market presence. Pharmaceutical companies are actively investing in clinical trials and targeted therapies to improve treatment efficacy and patient outcomes. Strategic partnerships with healthcare institutions, biotechnology firms, and research organizations are helping accelerate the development of new treatment options. Expanding global distribution networks and increasing access to advanced cancer medications are also key strategies adopted by major industry players to enhance their competitive position in the market.
Companies Covered in This Report:
By Drug Class
Please Note: It will take 5 business days to complete the report upon order confirmation.
Key Insights:
- Prostate Cancer Hormone Therapy Market Size (2025E): US$ 20.54 Bn
- Projected Market Value (2032F): US$ 79.89 Bn
- Global Market Growth Rate (CAGR 2025 to 2032): 20.9%
The prostate cancer hormone therapy market focuses on therapeutic approaches designed to reduce or block the production and action of male hormones (androgens) that stimulate prostate cancer growth. Hormone therapy plays a vital role in treating advanced and metastatic prostate cancer and is often used in combination with other treatment approaches such as radiation therapy or chemotherapy. Continuous advancements in targeted therapies, improved diagnostic methods, and the development of next-generation androgen receptor inhibitors have significantly improved treatment outcomes. Growing awareness about early diagnosis and personalized treatment strategies is further strengthening market growth. Additionally, increasing investments in oncology research and the introduction of innovative drug formulations are expected to expand treatment options and improve patient care over the forecast period.
Market Growth Drivers:
The global prostate cancer hormone therapy market is witnessing strong growth due to the rising prevalence of prostate cancer and increasing awareness regarding early detection and treatment. Advances in targeted therapies and the development of novel androgen receptor inhibitors have significantly improved the effectiveness of hormone therapy treatments. Increasing investments in oncology research, expanding clinical trials, and regulatory approvals for innovative drugs are further supporting market expansion. Additionally, the growing aging male population worldwide, which is more susceptible to prostate cancer, is driving demand for effective hormone therapy options. Improved healthcare infrastructure and expanding access to advanced cancer treatments are also contributing to sustained market growth.
Market Restraints:
Despite the strong growth outlook, the prostate cancer hormone therapy market faces several challenges. High treatment costs associated with advanced hormone therapy drugs may limit accessibility in developing regions and cost-sensitive healthcare systems. Hormone therapies can also cause side effects such as fatigue, bone density loss, metabolic changes, and cardiovascular risks, which may affect patient compliance and long-term treatment outcomes. Additionally, the development of resistance to hormone therapies in certain advanced stages of prostate cancer may reduce treatment effectiveness over time. Regulatory hurdles and lengthy drug approval processes may also delay the introduction of innovative therapies to the market.
Market Opportunities:
The prostate cancer hormone therapy market presents significant growth opportunities driven by continuous innovation in oncology therapeutics. Advances in precision medicine and biomarker-based treatment strategies are creating opportunities for more personalized and effective hormone therapy regimens. Increasing investments in research and development by pharmaceutical companies are expected to lead to the discovery of next-generation androgen receptor inhibitors and combination therapies. Emerging markets in Asia Pacific and Latin America offer substantial growth potential due to improving healthcare infrastructure and increasing awareness about cancer treatment options. Additionally, expanding telemedicine services and online pharmacy distribution channels are expected to enhance patient access to hormone therapy medications.
Key Questions Answered in the Report:
- What are the primary factors driving the global prostate cancer hormone therapy market's growth?
- Which regions and market segments are experiencing the highest demand for prostate cancer hormone therapies?
- How are innovations in targeted oncology therapies influencing market dynamics?
- Who are the key players in the prostate cancer hormone therapy market, and what strategies are they adopting to remain competitive?
- What are the emerging trends and future projections for the global prostate cancer hormone therapy market?
Leading companies in the global prostate cancer hormone therapy market are focusing on research and development, strategic collaborations, and the introduction of innovative drug formulations to strengthen their market presence. Pharmaceutical companies are actively investing in clinical trials and targeted therapies to improve treatment efficacy and patient outcomes. Strategic partnerships with healthcare institutions, biotechnology firms, and research organizations are helping accelerate the development of new treatment options. Expanding global distribution networks and increasing access to advanced cancer medications are also key strategies adopted by major industry players to enhance their competitive position in the market.
Companies Covered in This Report:
- Astellas Pharma Inc.
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Bayer AG
- Sanofi
- Myovant Sciences
- Tolmar Pharmaceuticals
- Foresee Pharmaceuticals Co., Ltd.
- AbbVie Inc.
- Endo International plc
- Clovis Oncology
- Exelixis, Inc.
- NantKwest (ImmunityBio)
- Bristol Myers Squibb
- Novartis AG
- Dr. Reddy’s Laboratories
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals
By Drug Class
- Androgen Receptor Inhibitors
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- GnRH Receptor Antagonists
- Anti-Androgens
- Combination Therapies
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
- Hormone-Sensitive Prostate Cancer (HSPC)
- Oral
- Parenteral
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Please Note: It will take 5 business days to complete the report upon order confirmation.
Table of Contents
193 Pages
- 1. Executive Summary
- 1.1. Global Prostate Cancer Hormone Therapy Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
- 2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
- 2.3. Macro-economic Factors
- 2.3.1. Global Sectoral Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors - Relevance and Impact
- 3. Value Added Insights
- 3.1. Tool Adoption Analysis
- 3.2. Regulatory Landscape
- 3.3. Value Chain Analysis
- 3.4. PESTLE Analysis
- 3.5. Porter’s Five Force Analysis
- 4. Price Analysis, 2024A
- 4.1. Key Highlights
- 4.2. Key Factors Impacting Deployment Costs
- 4.3. Pricing Analysis, By Component Type
- 5. Global Prostate Cancer Hormone Therapy Market Outlook
- 5.1. Key Highlights
- 5.1.1. Market Volume (Units) Projections
- 5.1.2. Market Size (US$ Bn) and Y-o-Y Growth
- 5.1.3. Absolute $ Opportunity
- 5.2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
- 5.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
- 5.2.2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
- 5.3. Global Prostate Cancer Hormone Therapy Market Outlook: Drug Class
- 5.3.1. Introduction / Key Findings
- 5.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Drug Class, 2019-2024
- 5.3.3. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Class, 2025-2032
- 5.3.3.1. Androgen Receptor Inhibitors
- 5.3.3.2. Gonadotropin-Releasing Hormone (GnRH) Agonists
- 5.3.3.3. GnRH Receptor Antagonists
- 5.3.3.4. Anti-Androgens
- 5.3.3.5. Combination Therapies
- 5.3.4. Market Attractiveness Analysis: Drug Class
- 5.4. Global Prostate Cancer Hormone Therapy Market Outlook: Disease State
- 5.4.1. Introduction / Key Findings
- 5.4.2. Historical Market Size (US$ Bn) Analysis, By Disease State, 2019-2024
- 5.4.3. Market Size (US$ Bn) Analysis and Forecast, By Disease State, 2025-2032
- 5.4.3.1. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- 5.4.3.2. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
- 5.4.3.3. Hormone-Sensitive Prostate Cancer (HSPC)
- 5.4.4. Market Attractiveness Analysis: Disease State
- 5.5. Global Prostate Cancer Hormone Therapy Market Outlook: Route of Administration
- 5.5.1. Introduction / Key Findings
- 5.5.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2024
- 5.5.3. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 5.5.3.1. Oral
- 5.5.3.2. Parenteral
- 5.5.4. Market Attractiveness Analysis: Route of Administration
- 5.6. Global Prostate Cancer Hormone Therapy Market Outlook: Distribution Channel
- 5.6.1. Introduction / Key Findings
- 5.6.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
- 5.6.3. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 5.6.3.1. Hospital Pharmacies
- 5.6.3.2. Retail Pharmacies & Drug Stores
- 5.6.3.3. Online Pharmacies
- 5.6.4. Market Attractiveness Analysis: Distribution Channel
- 6. Global Prostate Cancer Hormone Therapy Market Outlook: Region
- 6.1. Key Highlights
- 6.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019-2024
- 6.3. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025-2032
- 6.3.1. North America
- 6.3.2. Europe
- 6.3.3. East Asia
- 6.3.4. South Asia and Oceania
- 6.3.5. Latin America
- 6.3.6. Middle East & Africa
- 6.4. Market Attractiveness Analysis: Region
- 7. North America Prostate Cancer Hormone Therapy Market Outlook
- 7.1. Key Highlights
- 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Drug Class
- 7.2.3. By Disease State
- 7.2.4. By Route of Administration
- 7.2.5. By Distribution Channel
- 7.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. U.S.
- 7.3.2. Canada
- 7.4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Component, 2025-2032
- 7.4.1. Androgen Receptor Inhibitors
- 7.4.2. Gonadotropin-Releasing Hormone (GnRH) Agonists
- 7.4.3. GnRH Receptor Antagonists
- 7.4.4. Anti-Androgens
- 7.4.5. Combination Therapies
- 7.5. Market Size (US$ Bn) Analysis and Forecast, By Disease State, 2025-2032
- 7.5.1. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- 7.5.2. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
- 7.5.3. Hormone-Sensitive Prostate Cancer (HSPC)
- 7.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 7.6.1. Oral
- 7.6.2. Parenteral
- 7.7. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 7.7.1. Hospital Pharmacies
- 7.7.2. Retail Pharmacies & Drug Stores
- 7.7.3. Online Pharmacies
- 7.8. Market Attractiveness Analysis
- 8. Europe Prostate Cancer Hormone Therapy Market Outlook
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Drug Class
- 8.2.3. By Disease State
- 8.2.4. By Route of Administration
- 8.2.5. By Distribution Channel
- 8.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. Germany
- 8.3.2. France
- 8.3.3. U.K.
- 8.3.4. Italy
- 8.3.5. Spain
- 8.3.6. Russia
- 8.3.7. Turkey
- 8.3.8. Rest of Europe
- 8.4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Class, 2025-2032
- 8.4.1. Androgen Receptor Inhibitors
- 8.4.2. Gonadotropin-Releasing Hormone (GnRH) Agonists
- 8.4.3. GnRH Receptor Antagonists
- 8.4.4. Anti-Androgens
- 8.4.5. Combination Therapies
- 8.5. Market Size (US$ Bn) Analysis and Forecast, By Disease State, 2025-2032
- 8.5.1. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- 8.5.2. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
- 8.5.3. Hormone-Sensitive Prostate Cancer (HSPC)
- 8.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 8.6.1. Oral
- 8.6.2. Parenteral
- 8.7. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 8.7.1. Hospital Pharmacies
- 8.7.2. Retail Pharmacies & Drug Stores
- 8.7.3. Online Pharmacies
- 8.8. Market Attractiveness Analysis
- 9. East Asia Prostate Cancer Hormone Therapy Market Outlook
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Drug Class
- 9.2.3. By Disease State
- 9.2.4. By Route of Administration
- 9.2.5. By Distribution Channel
- 9.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
- 9.4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Class, 2025-2032
- 9.4.1. Androgen Receptor Inhibitors
- 9.4.2. Gonadotropin-Releasing Hormone (GnRH) Agonists
- 9.4.3. GnRH Receptor Antagonists
- 9.4.4. Anti-Androgens
- 9.4.5. Combination Therapies
- 9.5. Market Size (US$ Bn) Analysis and Forecast, By Disease State, 2025-2032
- 9.5.1. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- 9.5.2. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
- 9.5.3. Hormone-Sensitive Prostate Cancer (HSPC)
- 9.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 9.6.1. Oral
- 9.6.2. Parenteral
- 9.7. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 9.7.1. Hospital Pharmacies
- 9.7.2. Retail Pharmacies & Drug Stores
- 9.7.3. Online Pharmacies
- 9.8. Market Attractiveness Analysis
- 10. South Asia & Oceania Prostate Cancer Hormone Therapy Market Outlook
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Drug Class
- 10.2.3. By Disease State
- 10.2.4. By Route of Administration
- 10.2.5. By Distribution Channel
- 10.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. India
- 10.3.2. Southeast Asia
- 10.3.3. ANZ
- 10.3.4. Rest of South Asia & Oceania
- 10.4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Class, 2025-2032
- 10.4.1. Androgen Receptor Inhibitors
- 10.4.2. Gonadotropin-Releasing Hormone (GnRH) Agonists
- 10.4.3. GnRH Receptor Antagonists
- 10.4.4. Anti-Androgens
- 10.4.5. Combination Therapies
- 10.5. Market Size (US$ Bn) Analysis and Forecast, By Disease State, 2025-2032
- 10.5.1. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- 10.5.2. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
- 10.5.3. Hormone-Sensitive Prostate Cancer (HSPC)
- 10.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 10.6.1. Oral
- 10.6.2. Parenteral
- 10.7. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 10.7.1. Hospital Pharmacies
- 10.7.2. Retail Pharmacies & Drug Stores
- 10.7.3. Online Pharmacies
- 10.8. Market Attractiveness Analysis
- 11. Latin America Prostate Cancer Hormone Therapy Market Outlook
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Drug Class
- 11.2.3. By Disease State
- 11.2.4. By Route of Administration
- 11.2.5. By Distribution Channel
- 11.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. Brazil
- 11.3.2. Mexico
- 11.3.3. Rest of Latin America
- 11.4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Class, 2025-2032
- 11.4.1. Androgen Receptor Inhibitors
- 11.4.2. Gonadotropin-Releasing Hormone (GnRH) Agonists
- 11.4.3. GnRH Receptor Antagonists
- 11.4.4. Anti-Androgens
- 11.4.5. Combination Therapies
- 11.5. Market Size (US$ Bn) Analysis and Forecast, By Disease State, 2025-2032
- 11.5.1. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- 11.5.2. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
- 11.5.3. Hormone-Sensitive Prostate Cancer (HSPC)
- 11.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 11.6.1. Oral
- 11.6.2. Parenteral
- 11.7. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 11.7.1. Hospital Pharmacies
- 11.7.2. Retail Pharmacies & Drug Stores
- 11.7.3. Online Pharmacies
- 11.8. Market Attractiveness Analysis
- 12. Middle East & Africa Prostate Cancer Hormone Therapy Market Outlook
- 12.1. Key Highlights
- 12.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 12.2.1. By Country
- 12.2.2. By Drug Class
- 12.2.3. By Disease State
- 12.2.4. By Route of Administration
- 12.2.5. By Distribution Channel
- 12.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 12.3.1. GCC Countries
- 12.3.2. Egypt
- 12.3.3. South Africa
- 12.3.4. Northern Africa
- 12.3.5. Rest of Middle East & Africa
- 12.4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Class, 2025-2032
- 12.4.1. Androgen Receptor Inhibitors
- 12.4.2. Gonadotropin-Releasing Hormone (GnRH) Agonists
- 12.4.3. GnRH Receptor Antagonists
- 12.4.4. Anti-Androgens
- 12.4.5. Combination Therapies
- 12.5. Market Size (US$ Bn) Analysis and Forecast, By Disease State, 2025-2032
- 12.5.1. Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- 12.5.2. Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
- 12.5.3. Hormone-Sensitive Prostate Cancer (HSPC)
- 12.6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025-2032
- 12.6.1. Oral
- 12.6.2. Parenteral
- 12.7. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
- 12.7.1. Hospital Pharmacies
- 12.7.2. Retail Pharmacies & Drug Stores
- 12.7.3. Online Pharmacies
- 12.8. Market Attractiveness Analysis
- 13. Competition Landscape
- 13.1. Market Share Analysis, 2024
- 13.2. Market Structure
- 13.2.1. Competition Intensity Mapping By Market
- 13.2.2. Competition Dashboard
- 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 13.3.1. Astellas Pharma Inc.
- 13.3.1.1. Overview
- 13.3.1.2. Segments and Components
- 13.3.1.3. Key Financials
- 13.3.1.4. Market Developments
- 13.3.1.5. Market Strategy
- 13.3.2. Pfizer Inc.
- 13.3.3. Johnson & Johnson Services, Inc.
- 13.3.4. Bayer AG
- 13.3.5. Sanofi
- 13.3.6. Myovant Sciences
- 13.3.7. Tolmar Pharmaceuticals
- 13.3.8. Foresee Pharmaceuticals Co., Ltd.
- 13.3.9. AbbVie Inc.
- 13.3.10. Endo International plc
- 13.3.11. Clovis Oncology
- 13.3.12. Exelixis, Inc.
- 13.3.13. NantKwest (ImmunityBio)
- 13.3.14. Bristol Myers Squibb
- 13.3.15. Novartis AG
- 13.3.16. Dr. Reddy’s Laboratories
- 13.3.17. Sun Pharmaceutical Industries Ltd.
- 13.3.18. Teva Pharmaceuticals
- 14. Appendix
- 14.1. Research Methodology
- 14.2. Research Assumptions
- 14.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
